Search results for "Tumor immunology"

showing 10 items of 21 documents

Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment

2015

Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cel…

0301 basic medicineCancer Researchmedicine.medical_treatmentCellOsteoclastsAntineoplastic AgentsCD8-Positive T-LymphocytesBiologyBioinformaticsT-Lymphocytes RegulatoryImmunomodulation03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemBone MarrowDrug DiscoverymicroRNAmedicineHumansMultiple myelomamiRNAPharmacologyImmune-responseTumor immunology.MacrophagesMicroRNADendritic CellsImmunotherapyTh1 CellsPlasma cell neoplasmmedicine.diseaseGene Expression Regulation NeoplasticKiller Cells NaturalMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunotherapyBone marrowMultiple MyelomaReprogrammingCurrent Cancer Drug Targets
researchProduct

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities

2021

Simple Summary The growing interest in immunotherapy for the treatment of multiple myeloma demands a deep knowledge of the complex interactions between malignant and immune cells within the bone marrow. Indeed, understanding the cellular and molecular mechanisms underlying this network should represent the basis for the design of novel patient-oriented biological therapeutic approaches. Here, we describe the role of the main immune components of the myeloma niche along disease evolution and their implication in impairing/improving the response to anti-cancer treatments. Additionally, we provided an overview of the potential weakness of this pro-tumor interplay, evidencing novel therapeutic …

0301 basic medicineCancer Researchmedicine.medical_treatmentReview03 medical and health sciences0302 clinical medicineMedicinetumor immunologyElotuzumabMultiple myelomaRC254-282IsatuximabMonoclonal antibodiebusiness.industryDaratumumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseasePomalidomideanti-cancer immune responseThalidomidemultiple myeloma030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyimmunotherapymonoclonal antibodiesbusinessMonoclonal gammopathy of undetermined significancemedicine.drugCancers
researchProduct

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

2016

// Alessandra Romano 1 , Nunziatina Laura Parrinello 1 , Calogero Vetro 1 , Daniele Tibullo 1 , Cesarina Giallongo 1 , Piera La Cava 1 , Annalisa Chiarenza 1 , Giovanna Motta 1 , Anastasia L. Caruso 1 , Loredana Villari 2 , Claudio Tripodo 3 , Sebastiano Cosentino 4 , Massimo Ippolito 4 , Ugo Consoli 5 , Andrea Gallamini 6 , Stefano Pileri 7 , Francesco Di Raimondo 1 1 Division of Hematology, AOU “Policlinico - Vittorio Emanuele”, University of Catania, Catania, Italy 2 Division of Pathology, AOU “Policlinico - Vittorio Emanuele”, Catania, Italy 3 Tumor Immunology Unit, Department of Health Science, University of Palermo, Palermo, Italy 4 Nuclear Medicine Center, Azienda Ospedaliera Cannizz…

0301 basic medicineMaleCancer ResearchMyeloidNeutrophilsmedicine.medical_treatmentArginase-1Treatment outcomeKaplan-Meier EstimateGastroenterology0302 clinical medicineHematologyHealthy subjectsImmunosuppressionHematologyMiddle AgedPrognosisHodgkin DiseaseTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleArginase-1; Hodgkin Lymphoma; PET-2Tumor immunologyResearch PaperAdultmedicine.medical_specialtyPrognostic variableAdolescentAntineoplastic AgentsPET-2Sensitivity and SpecificityDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansProgression-free survivalAgedArginasebusiness.industryMyeloid-Derived Suppressor Cells030104 developmental biologyPotential biomarkersImmunologyHodgkin lymphomabusinessHodgkin lymphoma030215 immunologyOncotarget
researchProduct

IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis

2018

Interleukin (IL)-25, a member of the IL-17 cytokine superfamily, is produced by immune and non-immune cells and exerts type 2 pro-inflammatory effects in vitro and in vivo. The IL-25 receptor(R) is composed of the IL-17RA/IL-17RB subunits. Previous work showed that germinal centre (GC)-derived B-cell non Hodgkin lymphomas (B-NHL) expressed IL-17AR, formed by IL-17RA and IL-17RC subunits, and IL-17A/IL-17AR axis promoted B-NHL growth by stimulating neoangiogenesis. Here, we have investigated expression and function of IL-25/IL-25R axis in lymph nodes from human GC-derived B-NHL, i.e. Follicular Lymphoma (FL,10 cases), Diffuse Large B Cell Lymphoma (6 cases) and Burkitt Lymphoma (3 cases). Tu…

0301 basic medicinelcsh:Immunologic diseases. AllergyPathologymedicine.medical_specialtyAngiogenesismedicine.medical_treatmentImmunologyFollicular lymphomalcsh:RC254-282Angiogenesis; B lymphocytes; B-NHL; Cytokines; IL-25; Tumor immunology; Immunology and Allergy; Immunology; Oncology03 medical and health sciencesangiogenesisIL-25immune system diseaseshemic and lymphatic diseasesmedicineImmunology and AllergyCytokineOriginal ResearchB lymphocyteChemistryGerminal centerInterleukinmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscytokinesLymphomaAngiogenesi030104 developmental biologyCytokineOncologyCancer researchB-Cell Non-Hodgkin LymphomaTumor immunologyB-NHLb lymphocyteslcsh:RC581-607Diffuse large B-cell lymphoma
researchProduct

Tumor Recognition by the Cellular Immune System: New Aspects of Tumor Immunology

1997

Antigen Presentationbusiness.industryT-LymphocytesImmunologyAntigen presentationImmune systemAntigenAntigens NeoplasmImmune SystemNeoplasmsImmunologyAnimalsHumansImmunology and AllergyMedicinebusinessTumor immunologyInternational Reviews of Immunology
researchProduct

Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Pa…

2014

BackgroundThe importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans.MethodsIn this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests.ResultsWe found that chemotherapy induces lymphopenia and that a significantly hig…

CD4-Positive T-LymphocytesMaleSkin Neoplasmsmedicine.medical_treatmentCancer TreatmentGene ExpressionNK cellsLymphocyte ActivationT-Lymphocytes RegulatoryLeukocyte CountCellular typesMedicine and Health SciencesCytotoxic T cellProspective StudiesNeoplasm MetastasisProspective cohort studyImmune ResponseMelanomaAged 80 and overMultidisciplinarymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMelanomaQRMiddle AgedFlow CytometryPrognosis3. Good healthDacarbazineKiller Cells NaturalTreatment OutcomeOncologyCutaneous MelanomaMedicineWhite blood cellsFemaleImmunotherapymedicine.drugResearch ArticleTumor ImmunologyAdultCell biologyBlood cellsCell SurvivalDacarbazineScienceImmune CellsImmunologyLocally advancedT cellsMalignant Skin NeoplasmsDermatologyCancer ImmunotherapyFlow cytometryImmune systemCell Line TumormedicineHumansAntineoplastic Agents AlkylatingAgedChemotherapyBiology and life sciencesbusiness.industrymedicine.diseaseAnimal cellsImmunologyCancer researchClinical ImmunologybusinessTranscription FactorsPLoS ONE
researchProduct

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome

2021

BackgroundBreast cancer (BC) progression to metastatic disease is the leading cause of death in women worldwide. Metastasis is driven by cancer stem cells (CSCs) and signals from their microenvironment. Interleukin (IL) 30 promotes BC progression, and its expression correlates with disease recurrence and mortality. Whether it acts by regulating BCSCs is unknown and could have significant therapeutic implications.MethodsHuman (h) and murine (m) BCSCs were tested for their production of and response to IL30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array. Immunocompetent mice were used to investigate the role of BCSC-derived IL30 on tumor…

Cancer Research2434ImmunologyTriple Negative Breast NeoplasmsBiologyInterleukin-23Paracrine signallingMiceCancer stem cellCell Line Tumorbreast neoplasmsImmunology and Allergytumor microenvironmentAnimalsHumans1506Autocrine signallingRC254-282PharmacologyTumor microenvironmentbreast neoplasms cytokines tumor microenvironmentInterleukinsInnate lymphoid cellNeoplasms. Tumors. Oncology. Including cancer and carcinogensFOXP3Basic Tumor ImmunologyDendritic cellcytokinesChemokine CXCL10Autocrine CommunicationOncologyKLF4Cancer researchNeoplastic Stem CellsMolecular MedicineFemaleJournal for Immunotherapy of Cancer
researchProduct

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

2015

Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8…

Cell typeImmunologySettore MED/08 - Anatomia PatologicaangiogenesisB non-Hodgkin lymphomahemic and lymphatic diseasesmedicineIL-17AImmunology and Allergytumor immunologyCXCL13B-cell lymphomaangiogenesis; B non-Hodgkin lymphoma; GC B cells; IL-17A; IL-17A receptor; tumor immunology; Immunology and Allergy; Oncology; ImmunologyB cellOriginal ResearchSevere combined immunodeficiencybusiness.industryIL-17A receptorGerminal centerInterleukinangiogenesimedicine.diseaseMolecular biologyGC B cellmedicine.anatomical_structureOncologyCell cultureImmunologyGC B cellsbusiness
researchProduct

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples.

2013

Flow cytometry is the prototypical assay for multi-parameter single cell analysis, and is essential in vaccine and biomarker research for the enumeration of antigen-specific lymphocytes that are often found in extremely low frequencies (0.1% or less). Standard analysis of flow cytometry data relies on visual identification of cell subsets by experts, a process that is subjective and often difficult to reproduce. An alternative and more objective approach is the use of statistical models to identify cell subsets of interest in an automated fashion. Two specific challenges for automated analysis are to detect extremely low frequency event subsets without biasing the estimate by pre-processing…

Computer scienceAdaptive Immunitycomputer.software_genre0302 clinical medicineSingle-cell analysisEnumerationBiology (General)Immune ResponseEvent (probability theory)0303 health sciencesEcologymedicine.diagnostic_testT CellsStatisticsFlow Cytometry3. Good healthComputational Theory and MathematicsData modelModeling and SimulationMedicineData miningImmunotherapyResearch ArticleTumor ImmunologyQH301-705.5Immune CellsImmunologyContext (language use)BiostatisticsModels BiologicalFlow cytometry03 medical and health sciencesCellular and Molecular NeuroscienceGeneticsmedicineHumansSensitivity (control systems)Statistical MethodsImmunoassaysMolecular BiologyBiologyEcology Evolution Behavior and Systematics030304 developmental biologybusiness.industryImmunityReproducibility of ResultsPattern recognitionStatistical modelImmunologic SubspecialtiesLymphocyte SubsetsImmunologic TechniquesClinical ImmunologyArtificial intelligencebusinesscomputerMathematics030215 immunologyPLoS computational biology
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct